Evidence map›Paper›PMID 37386883›Full record

ArticleThe Journal of infectious diseases2024

Circulating Biomarkers, Fraction of Exhaled Nitric Oxide, and Lung Function in Patients With Human Immunodeficiency Virus and Tuberculosis.

Pholo Maenetje, Yeonsoo Baik, Diana B Schramm, Mboyo Di-Tamba Willy Vangu, Robert S Wallis, Mandla Mlotshwa, Caroline T Tiemessen, Yun Li, Hardy Kornfeld, Gavin Churchyard and 2 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of infectious diseases, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Post-tuberculosis lung disease in treated extra-pulmonary tuberculosis.American journal of respiratory and critical care medicine · 2026
    Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Pholo MaenetjeThe Aurum Institute, Johannesburg, South Africa.
Yeonsoo BaikDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Diana B SchrammCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
Mboyo Di-Tamba Willy VanguDepartment of Nuclear Medicine, Charlotte Maxeke Johannesburg Academic Hospital, University of the Witwatersrand, Johannesburg, South Africa.
Robert S WallisThe Aurum Institute, Johannesburg, South Africa.
Mandla MlotshwaThe Aurum Institute, Johannesburg, South Africa.
Caroline T TiemessenCentre for HIV and STIs, National Institute for Communicable Diseases, Johannesburg, South Africa.
Yun LiDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Hardy KornfeldDepartment of Medicine, University of Massachusetts Chan Medical School, Worcester, USA.ORCID 0000-0002-8970-7306
Gavin ChurchyardThe Aurum Institute, Johannesburg, South Africa.
Sara C AuldDepartments of Medicine and Epidemiology, Emory University School of Medicine and Rollins School of Public Health, Atlanta, Georgia, USA.
Gregory P BissonDepartment of Biostatistics, Epidemiology, and Informatics, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania, USA.
University of the Witwatersrand · ZAUniversity of Pennsylvania · USAurum Institute · ZAEmory University · USUniversity of Massachusetts Chan Medical School · USVanderbilt University · US

Funding

Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
Virology and Molecular Biomarkers CoreP30AI050409 · NIAID · EMORY UNIVERSITY · PI Carlos del Rio · 2002 to 2026
$74.0M
Aurum Clinical Trials UnitUM1AI154463 · NIAID · AURUM INSTITUTE NPC · PI Gavin John Churchyard · 2021 to 2026
$8.1M
Emory/Georgia TB Research Advancement Center (TRAC)P30AI168386 · NIAID · EMORY UNIVERSITY · PI Jeffrey M Collins · 2022 to 2026
$5.8M
Inflammation and Fibrosis in Pulmonary TB: the INFIN-TB StudyR01AI166988 · NIAID · EMORY UNIVERSITY · PI Sara Auld, GREGORY P. BISSON · 2022 to 2026
$5.1M
Rapid Immune Restoration and Lung Injury in HIV/TBR01AI120821 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI BISSON, GREGORY P. · 2015 to 2019
$3.3M
Impact of HIV infection on early responses to TB exposureK23AI134182 · NIAID · EMORY UNIVERSITY · PI AULD, SARA · 2018 to 2023
$972k
NIAID NIH HHS K23 AI134182NIAID NIH HHS P30 AI045008NIAID NIH HHS P30 AI050409NIAID NIH HHS P30 AI168386NIAID NIH HHS R01 AI166988NIAID NIH HHS UM1 AI154463NIH HHS R01AI120821
6 · The paper itself

Abstract

backgroundIdentification of proinflammatory factors responding to Mycobacterium tuberculosis is important to reduce long-term sequelae of pulmonary tuberculosis (TB).

methodsWe examined the association between plasma biomarkers, the fraction of exhaled nitric oxide (FeNO), and lung function among a prospective cohort of 105 adults newly diagnosed with TB/human immunodeficiency virus (HIV) in South Africa. Participants were followed for 48 weeks from antiretroviral therapy (ART) initiation with serial assessments of plasma biomarkers, FeNO, lung function, and respiratory symptoms. Linear regression and generalized estimating equations were used to examine the associations at baseline and over the course of TB treatment, respectively.

resultsAt baseline, higher FeNO levels were associated with preserved lung function, whereas greater respiratory symptoms and higher interleukin (IL)-6 plasma levels were associated with worse lung function. After ART and TB treatment initiation, improvements in lung function were associated with increases in FeNO (rate ratio [RR] = 86 mL, 95% confidence interval [CI] = 34-139) and decreases in IL-6 (RR = -118 mL, 95% CI = -193 to -43) and vascular endothelial growth factor ([VEGF] RR = -178 mL, 95% CI = -314 to -43).

conclusionsCirculating IL-6, VEGF, and FeNO are associated with lung function in adults being treated for TB/HIV. These biomarkers may help identify individuals at higher risk for post-TB lung disease and elucidate targetable pathways to modify the risk of chronic lung impairment among TB survivors.

Indexed as

HIV InfectionsTuberculosisAdultBiomarkersHIVHumansInterleukin-6LungNitric OxideProspective StudiesVascular Endothelial Growth Factor ABiomarkersInterleukin-6Nitric OxideVascular Endothelial Growth Factor Afraction of exhaled nitric oxideHIVinterleukin-6pulmonary functiontuberculosis

Identifiers

PMID37386883
PMCPMC10938205
OpenAlexW4382630726

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.